Clinical Trial News and Research

RSS

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Array BioPharma Inc. announced today that a $5 million milestone was achieved after the start of Array's Phase 3 clinical trial in patients with low-grade serous ovarian cancer.

2 Jul 2013

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemophilia and rare bleeding disorders.

2 Jul 2013

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

Idera Pharmaceuticals, Inc. announced results of a Phase 1 clinical trial of IMO-8400, a first-in-class antagonist of Toll-like Receptors 7, 8, and 9 being developed for potential applications in autoimmune and inflammatory diseases.

2 Jul 2013

OBI advances Phase IIb clinical trial of Oxycyte for treatment of TBI

Oxygen Biotherapeutics, Inc., ("OBI") (NASDAQ: OXBT), today announced enrollment of the first subject in the second cohort of its global Phase IIb clinical trial to investigate the safety and tolerability of Oxycyte® in patients with severe, non-penetrating traumatic brain injury ("STOP-TBI").

2 Jul 2013

Biomarker indicates which women are at risk for breast cancer recurrence after tamoxifen

A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment.

30 Jun 2013

RPCI scientists assess safety and efficacy of immunotherapy approach to treat advanced melanoma

A new clinical research study at Roswell Park Cancer Institute (RPCI) will assess the safety and efficacy of a novel immunotherapy approach to treating advanced melanoma. Developed at RPCI by Roswell Park researchers, the investigational vaccine shows promise for treating tumors in patients with stage III/stage IV melanoma, and perhaps as a future therapy for other solid-tumor cancers as well.

30 Jun 2013

Case Comprehensive Cancer Center secures "outstanding" rating from NCI

The Case Comprehensive Cancer Center (CCCC) again demonstrated the compelling power of partnership in securing an overall rating of "outstanding" and a five-year renewal of its grant from the National Cancer Institute (NCI).

28 Jun 2013

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.

28 Jun 2013

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira, the world's leading provider of injectable drugs and infusion technologies, today received a positive opinion from the European Medicines Agency Committee for Medicinal Products for Human Use, recommending the European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

28 Jun 2013

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today positive topline clinical results from a 6-week randomized, double-masked, placebo-controlled Phase 1b/2a study of EBI-005 in patients with dry eye disease.

28 Jun 2013

Curing type 1 diabetes: an interview with Dr. Habib Zaghouani, MU School of Medicine

Type 1 diabetes is an attack by the immune system of the islet of Langerhans within the pancreas. Basically, the islet of Langerhans harbor beta cells, which produce insulin and when the islets are attacked, the beta cells destruct and there is no more insulin. When the insulin level goes low, blood glucose levels go high and that creates a problem.

28 Jun 2013

Researchers create culturally targeted educational materials to help patients make health care decisions

Hispanic cancer patients rarely participate in clinical trials, but researchers want to tailor a Spanish DVD to help change this. To create a relevant educational tool, Moffitt Cancer Center researchers investigated why awareness of and participation in trials are so low in this population.

28 Jun 2013

Edge Therapeutics announces positive preliminary results from EG-1962 study for prevention of DCI

Edge Therapeutics announced today positive preliminary results from the first human use of EG-1962, the Company's novel bioabsorbable nimodipine microparticle formulation for the prevention of delayed cerebral ischemia, a life-threatening complication of subarachnoid hemorrhage, typically resulting from a ruptured brain aneurysm or traumatic brain injury.

27 Jun 2013

Researchers study possible alternative medications to treat cancer-related pain

Researchers at the Brain and Spine Institute at John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, are studying a possible alternative to side effect-ridden opioid-based medications to treat cancer-related pain.

27 Jun 2013

Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

Ambit Biosciences Corporation announced today data from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were featured in multiple presentations at the 18th Congress of the European Hematology Association in Stockholm, Sweden.

27 Jun 2013

FDA grants fast track designation to Genervon Biopharmaceuticals for ALS drug GM604

In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS. FDA said it met the necessary criteria.

27 Jun 2013

Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women

Sprout Pharmaceuticals, the Raleigh-based pharmaceutical company developing flibanserin, a treatment being evaluated for Hypoactive Sexual Desire Disorder in pre-menopausal women, confirmed today that the company has resubmitted the New Drug Application for flibanserin earlier this year and expects US Food and Drug Agency action before the end of 2013.

27 Jun 2013

Researchers develop breakthrough approach to reduce harmful effects from blood transfusions

Researchers from Case Western Reserve University School of Medicine have developed an unprecedented approach to restore nitric oxide to donated blood, a breakthrough that could dramatically reduce harmful effects from transfusions.

26 Jun 2013

New streamlined method harnesses tumor-infiltrating lymphocytes to improve outcomes

Jamie K. Teer, Ph.D., assistant member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, and colleagues have developed a new streamlined method to rapidly identify the genetic changes in small protein fragments unique to melanoma cancer cells.

26 Jun 2013

Researchers discover promising new way to treat HIV-related blood cancer

Researchers at the USC Norris Comprehensive Cancer Center have discovered a promising new way to treat a rare and aggressive blood cancer most commonly found in people infected with HIV.

26 Jun 2013

Clinical Trial News and Research

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

OBI advances Phase IIb clinical trial of Oxycyte for treatment of TBI

Biomarker indicates which women are at risk for breast cancer recurrence after tamoxifen

RPCI scientists assess safety and efficacy of immunotherapy approach to treat advanced melanoma

Case Comprehensive Cancer Center secures "outstanding" rating from NCI

Janssen receives complete response letter from FDA for XARELTO sNDA

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Curing type 1 diabetes: an interview with Dr. Habib Zaghouani, MU School of Medicine

Researchers create culturally targeted educational materials to help patients make health care decisions

Edge Therapeutics announces positive preliminary results from EG-1962 study for prevention of DCI

Researchers study possible alternative medications to treat cancer-related pain

Ambit Biosciences presents data from Phase 2 ACE study of quizartinib for treatment of AML

FDA grants fast track designation to Genervon Biopharmaceuticals for ALS drug GM604

Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women

Researchers develop breakthrough approach to reduce harmful effects from blood transfusions

New streamlined method harnesses tumor-infiltrating lymphocytes to improve outcomes

Researchers discover promising new way to treat HIV-related blood cancer

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer